LEADER 07862nam 2200433 450 001 9910564683703321 005 20221121230140.0 010 $a3-030-94740-8 035 $a(MiAaPQ)EBC6962846 035 $a(Au-PeEL)EBL6962846 035 $a(CKB)21639816000041 035 $a(PPN)26217314X 035 $a(EXLCZ)9921639816000041 100 $a20221121d2022 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aPrinciples in nursing practice in the era of COVID-19 /$fedited by Amanda Bergeron [and three others] 210 1$aCham, Switzerland :$cSpringer,$d[2022] 210 4$d©2022 215 $a1 online resource (185 pages) 311 08$aPrint version: Bergeron, Amanda Principles in Nursing Practice in the Era of COVID-19 Cham : Springer International Publishing AG,c2022 9783030947392 327 $aIntro -- Preface -- Contents -- 1: History and Epidemiology -- 1.1 History and Epidemiology -- 1.2 Timeline of Events -- 1.3 Coronavirus Virology -- 1.3.1 Variants of Concern -- 1.3.1.1 B.1.1.7 (Alpha) -- 1.3.1.2 B1.351 (Beta) -- 1.3.1.3 P.1 (Gamma) -- 1.3.1.4 B.1.617.2 (Delta) -- 1.4 Case Definition -- 1.5 Transmission -- 1.5.1 Animal Transmission -- 1.5.2 Person-to-Person -- 1.5.3 Asymptomatic/Presymptomatic Transmission -- 1.5.4 Vertical Transmission -- 1.6 Conclusion -- References -- 2: Prevention and Infection Control -- 2.1 General Infection Control Practices -- 2.1.1 Physical Distancing -- 2.1.2 Source Control Measures -- 2.1.3 Hand Hygiene -- 2.1.4 Ventilation -- 2.1.5 Other Environmental Controls -- 2.2 Screening and Quarantine -- 2.2.1 Screening -- 2.2.2 Contact Tracing -- 2.2.3 Quarantine -- 2.3 Infection Control and Prevention in COVID-19-Positive Patients -- 2.3.1 Personal Protective Equipment -- 2.3.1.1 Masks and Respirators -- 2.3.1.2 Eye Protection -- 2.3.1.3 Gloves -- 2.3.1.4 Gowns -- 2.3.2 Isolation Guidelines -- 2.3.2.1 Ending Isolation Precautions at the Hospital -- 2.3.2.2 Prevention and Isolation for Home Care -- 2.3.3 Optimization of PPE During Times of Shortages -- 2.3.4 Postmortem Guidance -- 2.4 Testing -- 2.4.1 Categories of Tests -- 2.4.1.1 Viral Tests -- 2.4.1.2 Antibody Tests -- 2.4.2 Administering Tests -- 2.4.3 Screening -- 2.4.4 Diagnosing -- 2.5 Immunity -- 2.5.1 Messenger Ribonucleic Acid-Based Vaccines -- 2.5.2 Viral Vector -- 2.5.3 Candidates for Vaccination -- 2.5.4 Natural Immunity -- 2.5.5 Booster and Supplemental Immunization -- 2.5.6 General Vaccination Considerations -- References -- 3: Manifestations of Coronavirus -- 3.1 Introduction -- 3.2 General -- 3.3 Respiratory -- 3.4 Cardiovascular -- 3.5 Neurology -- 3.6 Hematology -- 3.7 Gastroenterology. 327 $a3.8 Nephrology -- 3.9 Conclusion -- References -- 4: Pharmacological Management -- 4.1 Introduction -- 4.2 Antiviral Therapy -- 4.3 Remdesivir -- 4.4 Hydroxychloroquine and Chloroquine -- 4.5 Lopinavir/ritonavir -- 4.6 Ivermectin -- 4.7 Other Antivirals -- 4.8 Anti-SARS-CoV-2 Antibody Agents -- 4.9 Convalescent Plasma -- 4.10 Monoclonal Antibodies -- 4.11 Immunomodulators -- 4.12 Corticosteroids -- 4.13 Tocilizumab -- 4.14 Sarilumab -- 4.15 Baricitinib -- 4.16 Tofacitinib -- 4.17 Anakinra -- 4.18 Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Inhibitors -- 4.19 Conclusion -- References -- 5: Management of Oxygenation and Ventilation -- 5.1 Oxygenation and Ventilation -- 5.2 Dyspnea -- 5.3 Oxygen Saturation -- 5.4 Respiratory Rate -- 5.5 Arterial Blood Gas -- 5.6 Respiratory Support Options -- 5.7 Nasal Cannula and Face Mask -- 5.8 High Flow Nasal Cannula (HFNC) -- 5.9 Noninvasive Ventilation -- 5.10 Mechanical Ventilation -- 5.11 Additional Considerations -- 5.12 Role of Prone Positioning -- 5.13 Extracorporeal Membrane Oxygenation (ECMO) -- References -- 6: Systemic Complications -- 6.1 Shock -- 6.2 Sepsis/Septic Shock -- 6.3 Clinical Presentation of Sepsis -- 6.4 Acute Respiratory Distress Syndrome (ARDS) -- 6.4.1 Clinical Course of ARDS -- 6.5 Parallels and Differences Between COVID-19 and Non-SARS-CoV-2 Sepsis -- 6.5.1 Endothelial Cell Damage and Inflammation -- 6.6 Disseminated Intravascular Coagulopathy -- 6.6.1 Hypercoagulability in COVID-19 -- 6.7 Cardiac Manifestations of COVID-19 -- 6.7.1 Clinical Presentation -- 6.7.2 Heart Failure -- 6.8 Acute Kidney Injury -- 6.9 Conclusion -- References -- 7: Long-Term Sequalae of COVID-19 Infection -- 7.1 Epidemiology -- 7.2 Pathophysiology -- 7.3 Risk Factors -- 7.4 Symptoms (See Table 7.1) -- 7.4.1 Pulmonary -- 7.4.2 Cardiovascular. 327 $a7.4.3 Neurological -- 7.4.4 Renal -- 7.4.5 Endocrine -- 7.4.6 Gastrointestinal and Hepatobiliary -- 7.4.7 Dermatologic -- 7.4.8 Hematologic -- 7.5 Post-ICU Syndrome -- 7.5.1 Special Considerations -- 7.6 Treatments/Rehabilitation/COVID Clinics -- References -- 8: Outpatient Management of COVID-19 -- 8.1 Statistics -- 8.2 Mental Health -- 8.3 Symptom Management -- 8.4 Symptoms -- 8.5 Medications -- 8.6 Supportive Medications -- 8.7 Vitamins -- 8.8 Contraindications and Myths -- 8.8.1 Dexamethasone -- 8.8.2 ACE Inhibitors or ARBs -- 8.9 Monoclonal Antibodies -- 8.9.1 Eligibility Criteria -- 8.9.2 Administration of Monoclonal Antibodies -- 8.9.2.1 Sotrovimab -- 8.9.2.2 Casirivimab plus Imdevimab -- 8.9.2.3 Bamlanivimab plus Etesevimab -- 8.9.3 Clinical Trials of Monoclonal Antibodies -- 8.9.3.1 R10933-10987-COV-2067 Trial -- 8.9.3.2 COMET-ICE Trial -- 8.9.3.3 BLAZE-1 -- 8.10 Concomitant Medication Management -- 8.10.1 ACE Inhibitors and ARBs -- 8.10.2 Corticosteroids -- 8.10.3 Statins -- 8.10.4 NSAIDs -- 8.11 Outpatient Management for Specific Populations -- 8.11.1 Young Adults (18-29 Years Old) -- 8.11.2 Middle-Aged Adults (30-64 Years Old) -- 8.11.3 Elderly Adults (?65 Years Old) -- 8.11.4 Patients with Severe Comorbidities -- 8.11.5 Immunocompromised -- 8.12 Follow-up Care -- 8.13 Conclusion -- References -- 9: Implications for Pediatric Nursing Practice -- 9.1 Introduction -- 9.2 Pediatric Primary Care Considerations for COVID-19 -- 9.2.1 Pediatric-Specific Symptoms -- 9.2.2 Mental Health Concerns -- 9.2.3 Pediatric Care Delivery Disruptions -- 9.3 Critical Illness Resulting from COVID-19 Infection -- 9.3.1 Hospitalization for Children with COVID-19 -- 9.3.2 Multi-System Inflammatory Syndrome in Children (MIS-C) -- 9.3.3 Impacts of Pediatric Visitor Policies -- 9.3.4 Hospital Resource Utilization. 327 $a9.3.5 Financial Impact on Children's Hospitals -- 9.4 Impacts on School Systems -- 9.4.1 School Systems as Social Safety Nets -- 9.4.2 Impacts of School Closures on Academic Health -- 9.4.3 Food Insecurity Related to School Closures -- 9.4.4 Provision of Primary Care Services in School Settings -- 9.4.5 Community Partnerships with School Nurses -- 9.4.6 Impacts on Student Athletes -- 9.4.7 Social Worker Collaborations -- 9.5 Impacts on the Pediatric Nursing Workforce -- References -- 10: Psychological and Sociological Effects -- 10.1 Introduction -- 10.2 Healthcare Workers -- 10.2.1 Risk Factors -- 10.3 Post-Traumatic Stress Disorder (PTSD) -- 10.4 Anxiety and Depression -- 10.5 Insomnia -- 10.6 COVID Survivors -- 10.7 Effects of Quarantine -- 10.8 Treatment -- 10.9 Socioeconomic Effects of COVID-19 -- References. 606 $aNursing$xPractice 615 0$aNursing$xPractice. 676 $a610.73 702 $aAmanda Bergeron 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910564683703321 996 $aPrinciples in Nursing Practice in the Era of COVID-19$92837639 997 $aUNINA